↓ Skip to main content

ProQuest

A phase 1 dose-escalation and expansion study of binimetinib (MEK162), a potent and selective oral MEK1/2 inhibitor

Overview of attention for article published in British Journal of Cancer, February 2017
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (87th percentile)
  • Above-average Attention Score compared to outputs of the same age and source (60th percentile)

Mentioned by

blogs
1 blog
twitter
5 X users
patent
2 patents

Citations

dimensions_citation
75 Dimensions

Readers on

mendeley
99 Mendeley